ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

ClinicalTrials.gov ID: NCT05856526

Public ClinicalTrials.gov record NCT05856526. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome

Study identification

NCT ID
NCT05856526
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
43 participants

Conditions and interventions

Interventions

  • Placebo matching to spesolimab - solution for infusion Drug
  • Placebo matching to spesolimab - solution for injection Drug
  • Spesolimab - solution for infusion Drug
  • Spesolimab - solution for injection Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 11, 2023
Primary completion
Jan 12, 2025
Completion
Jul 30, 2025
Last update posted
Mar 11, 2026

2023 – 2025

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Mission Dermatology Center Rancho Santa Margarita California 92688
Yale University School of Medicine New Haven Connecticut 06519
Medical University of South Carolina Charleston South Carolina 29425
Virginia Clinical Research, Inc. Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05856526, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 11, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05856526 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →